- The trial is now open for recruitment.
- Clinical trial sites are located in Brisbane, Sydney and Melbourne, Australia.
- The ACCENT trial will test if narmafotinib helps people with pancreatic cancer have a better response to standard of care chemotherapies, gemcitabine and nab-paclitaxel.
- narmafotinib aims to break down the fibrotic tissue shield in pancreatic cancer to allow the chemotherapy to be more effective.
ACCENT pancreatic cancer clinical trial
A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of narmafotinib in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients
Amplia is developing a class of drug called a FAK inhibitor which we hope will make cancers more vulnerable and responsive to currently used treatments.
Amplia has successfully navigated vital research and development milestones to get to this stage. Our partnering clinical trial sites in Australia are now recruiting people with pancreatic cancer for our ACCENT trial to test if narmafotinib in combination with standard-of-care drugs gemcitabine and Nab-paclitaxel is effective in treating cancer.
Amplia has successfully navigated vital research and development milestones to get to this stage. Our partnering clinical trial sites in Australia are now recruiting people with pancreatic cancer for our ACCENT trial to test if narmafotinib in combination with standard-of-care drugs gemcitabine and Nab-paclitaxel is effective in treating cancer.
About the clinical trial
The ACCENT Phase 2 Clinical Trial (AMP945-PC-201) has strict entry criteria. Please note, Amplia is not recruiting patients directly and all enquiries for involvement must be made via our partnering clinical trial sites.
Are you eligible?
If you have been diagnosed with pancreatic cancer you may be eligible to participate.
There are many criteria to join a clinical trial and we recommend discussing your eligibility directly with your Oncologist.
There are many criteria to join a clinical trial and we recommend discussing your eligibility directly with your Oncologist.
